Drug Design of Sulfonylated MMP Inhibitors

Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications

Volumn , Issue , 2009, Pages 549-589

  Rossello, Armando ^a   Nuti, Elisa ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Drug design of sulfonylated MMP inhibitors; Matrix metalloproteinases (MMPs) and serious pathologies; Sulfonylated MMP inhibitors and new ZBG bearing inhibitor discovery

Indexed keywords

EID: 77949813516     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470508169.ch25     Document Type: Chapter

References (84)

1. Hanemaaijer, R.; Visser, H.; Koolwijk, P.; Sorsa, T.; Salo, T.; Golub, L. M.; van Hinsbergh, V. W. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv. Dent. Res. 1998, 12, 114-118.
2. Rajapakse, N.; Mendis, E.; Kim, M. M.; Kim, S. K. Sulfated glucosamine inhibits MMP-2 and MMP-9 expressions in human fibrosarcoma cells. Bioorg. Med. Chem. 2007, 15, 4891-4896.
3. Nuti, E.; Tuccinardi, T.; Rossello, A. matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Des. 2007, 13, 2087-2100.
4. Hidalgo, M. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Nat. Cancer Inst. 2001, 93, 178-193.
5. Overall, C. M.; Kleifeld, O. Validating matrix metalloproteinases as drug targets and antitargets for cancer therapy. Nat. Rev. Cancer 2006, 6, 227-239.
6. Brown, S.; Bernardo, M. M.; Li, Z. H.; Kotra, L. P.; Tanaka, Y.; Fridman, R.; Mobashery, S. Potent and selective mechanism-based inhibition of gelatinases. J. Am. Chem. Soc. 2000, 122, 6799-6800.
7. Nagase, H.; Woessner, J. F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274, 21491-21494.
8. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Tryggvason, K. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc. Natl. Acad. Sci. USA 2002, 99, 7414-7419.
9. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Isupov, M.; Lindqvist, Y.; Schneider, G.; Tryggvason, K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999, 284, 1667-1670.
10. Ra, H. J.; Parks, W. C. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007, 26, 587-596.
11. Spurlino, J. C.; Smallwood, A. M.; Carlton, D. D.; Banks, T. M.; Vavra, K. J.; Johnson, J. S.; Cook, E. R.; Falvo, J.; Wahl, R. C.; Pulvino, T. A.; Wendoloski, J. J.; Smith, D. L. Å structure of mature truncated human fibroblast collagenase. Proteins 1994, 19, 98-109.
12. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000, 43, 305-341.
13. Jacobsen, F. E.; Lewis, J. A.; Cohen, S. M. The design of inhibitors of medicinally relevant metalloproteins. Chem. Med. Chem. 2007, 2, 152-171.
14. Breuer, E.; Frant, J.; Reich, R. Recent non-hydroxamate matrix metalloproteinase inhibitors. Expert Opin. Ther. Pat. 2005, 15, 253-269.
15. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735-2776.
16. Babine, R. E.; Bender, S. L. Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev. 1997, 97, 1359-1472.
17. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295, 2387-2390.
18. Oreola, A.; Donini, T.; Kollman, P. A. Calculation and prediction of binding free energies for the matrix metalloproteinases. J. Med. Chem. 2000, 43, 4180-4188.
19. Browner, M. F.; Smith, W.W.; Castelhano, A. L. Crystal structures of matrilysin-inhibitor complexes. Biochemistry 1995, 34, 6602-6610.
20. Rowsell, S.;Hawatin, P.; Minshull, C. A.; Jepson, H.; Brockbank, S. M.V.; Barratt, D. G.; Slater, A. M.; McPheat, W. L.; Waterson, D.; Henney, A. M.; Pauptit, R. A. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 2002, 319, 173-181.
21. MacPherson, L. J.; Parker, D. T. Arylsulfonamido-substituted hydroxamic acids. EP 606046, 1994.
22. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L. J.; Hu, S. I.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.;Wilson, D. O.; Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525-2532.
23. Li, Y. C.; Zhang, X.; Melton, R.; Ganu, V.; Gonnella, N. C. Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Biochemistry 1998, 37, 14048-14056.
24. Terp, G. E.; Cruciani, G.; Christensen, I. T.; Jorgensen, F. S. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J. Med. Chem. 2002, 45, 2675-2684.
25. Hanessian, S.; Bouzbouz, S.; Boudon, A.; Tucker, G. C.; Peyroulan, D. Picking the S1, S10 and S20 pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 1691-1696.
26. Hanessian, S.; Moitessier, N. Sulfonamide-based acyclic and conformationally constrained MMP inhibitors: from computer-assisted design to nanomolar compounds. Curr. Top. Med. Chem. 2004, 4, 1269-1287.
27. Scozzafava, A.; Supuran, C. T. Protease inhibitors. Synthesis of potent matrix metalloproteinase and bacterial collagenase inhibitors incorporating N-4-nitrobenzylsulfonyl glycine hydroxamate moieties. J. Med. Chem. 2000, 43, 1858-1865.
28. Clare, B. W.; Scozzafava, A.; Supuran, C. T. Protease inhibitors: synthesis of a series of bacterial collagenase inhibitors of the sulfonyl amino acyl hydroxamate type. J. Med. Chem. 2001, 44, 2253-2258.
29. Santos, M. A.; Marques, S. M.; Tuccinardi, T.; Carelli, P.; Panelli, L.; Rossello, A. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors. Bioorg. Med. Chem. 2006, 14, 7539-7550.
30. Zook, S. E.; Dagnino, R., Jr.; Deason, M. E.; Bender, S. L.; Melnick, M. J. Metalloproteinase inhibitors, pharmaceutical composition containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation. WO 9720824, 1997.
31. Piscopio, A. D.; Rizzi, J. P. Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors. WO 9633172, 1996.
32. De, B.; Natchus, M. G.; Pikul, S.; Almstead, N. G.; Matthews, R. S.; Taiwo, Y. O.; Cheng, M. 1,4-Heterocyclic metalloprotease inhibitors. WO 9808825, 1998.
33. De, B.; Natchus, M. G.; Pikul, S.; Almstead, N. G.; Matthews, R. S.; Taiwo, Y. O.; Cheng, M. Heterocyclic metalloprotease inhibitors. WO 9808827, 1998.
34. Levin, J. I.; DiJoseph, J. F.; Killar, L. M.; Sung, A.;Walter, T.; Sharr, M. A.; Roth, C. E.; Skotnicki, J. S.; Albright, J. D. The synthesis and biological activity of a novel series of diazepine MMP inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2657-2662.
35. Almstead, N. G.; Bradley, R. S.; Pikul, S.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Gu, F.; Williams, L. E.; Hynd, B. A.; Janusz, M. J.; Dunaway, C. M.; Mieling, G. E. Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J. Med. Chem. 1999, 42, 4547-4562.
36. Damani, L. A., Ed. Metabolism of sulphur functional groups. Sulphur-Containing Drugs and Related Organic Compounds: Chemistry, Biochemistry and Toxicology, Vol. 1, PartsA and B; Ellis Horwood Limited: London, 1989.
37. Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.; Forsyth, P.; Edwards, D.; Margosiak, S.; Bender, S.; Truitt, G.; Wood, A.; Varki, N. M.; Appelt, K. Broad antitumour and antiangiogenic activities of AG3340, a potent and selectiveMMPinhibitor undergoing advanced oncology clinical trials. Ann. N.Y. Acad. Sci. 1999, 878, 236-270.
38. Lovejoy, B.;Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K. A.; Martin, R.; Van Wart, H.; Browner, M. F. Nat. Struct. Biol. 1999, 6, 217-221.
39. Tuccinardi, T.; Martinelli, A.; Nuti, E.; Carelli, P.; Balzano, F.; Uccello-Barretta, G.; Murphy, G.; Rossello, A. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg. Med. Chem. 2006, 14, 4260-4276.
40. Santos, O.; McDermott, C. D.; Daniels, R. G.; Appelt, K. Rodent pharmacokinetic and anti-tumour efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin. Exp. Metastasis. 1997, 15, 499-508.
41. Peterson, J. T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovas. Res. 2006, 69, 677-687.
42. Borden, P.; Solymar, D.; Sucharczuk, A.; Lindman, B.; Cannon, P.; Heller, R. A. J. Biol. Chem. 1996, 271, 23577-23581.
43. Barta, T. E.; Becker, D. P.; Bedell, L. J.; De Crescenzo, G. A.; McDonald, J. J.; Munie, G. E.; Rao, S.; Shieh, H. S.; Stegeman, R.; Stevens, A. M.;Villamil, C. I. Bioorg. Med. Chem. Lett. 2000, 10, 2815-2817.
44. Levin, J. I.; Chen, J.; Du, M.; Hogan, M.; Kincaid, S.; Nelson, F. C.; Venkatesan, A. M.; Wehr, T.; Zask, A.; DiJoseph, J.; Killar, L. M.; Skala, S.; Sung, A.; Sharr, M.; Roth, C.; Jin, G.; Cowling, R.; Mohler, K. M.; Black, R. A.; March, C. J.; Skotnicki, J. S. Bioorg. Med. Chem. Lett. 2001, 11, 2189-2192.
45. Nelson, F. C.; Delos Santos, E.; Levin, J. I.; Chen, J. M.; Skotnicki, J. S.; Di Joseph, J.; Sharr, M.; Sung, A.; Killar, L. M.; Cowling, R.; Jin, G.; Roth, C. E.; Albright, J. D. Bioorg. Med. Chem. Lett. 2002, 12, 2867-2870.
46. Cherney,R. J.; Mo, R.; Meyer, D. T.; Hardman, K. D.; Liu, R. Q.; Covington, M. B.; Qian, M.; Wasserman, Z. R.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P. J. Med. Chem. 2004, 47, 2981-2983.
47. Noe, M. C.; Natarajan, V.; Snow, S. L.; Mitchell, P. G.; Lopresti-Morrow, L.; Reeves, L. M.; Yocum, S. A.; Carty, T. J.; Barberia, J. A.; Sweeney, F. J.; Liras, J. L.; Vaughn, M.; Hardink, J. R.; Hawkins, J. M.; Tokar, C. Bioorg. Med. Chem. Lett. 2005, 15, 2808-2811.
48. Chen, J. M.; Nelson, F. C.; Levin, J. I.; Mobilio, D.; Moy, F. J.; NilaKantan, R.; Zask, A.; Powers, R. J. Am. Chem. Soc. 2000, 122, 9648-9654.
49. Whitlock, G. A.; Dack, K. N.; Dickinson, R. P.; Lewis, M. L. A novel series of highly selective inhibitors of MMP-3. Bioorg. Med. Chem. Lett. 2007, 17, 6750-6753.
50. Zook, S. E.; Dagnino, R., Jr.; Deason, M. E.; Bender, S. L.; Melnick, M. J. Metalloproteinase inhibitors, pharmaceutical composition containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation. WO9720824, 1997.
51. Rossello, A.; Nuti, E.; Orlandini, E.; Carelli, P.; Rapposelli, S.; Macchia, M.; Minutolo, F.; Carbonaro, L.; Albini, A.; Benelli, R.; Cercignani, G.; Murphy, G.; Balsamo, A. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg. Med. Chem. 2004, 12, 2441-2450.
52. Rossello, A.; Nuti, E.;Carelli, P.;Orlandini, E.;Macchia, M.; Nencetti, S.; Zandomeneghi, M.; Balzano, F.; Uccello Barretta, G.;Albini, A.; Benelli, R.; Cercignani, G.;Murphy, G.; Balsamo, A. N-i-propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. Bioorg. Med. Chem. Lett. 2005, 15, 1321-1326.
53. Nuti, E.; Conti, C.; Avramova, S. I.; Orlandini, E.; Nencetti, S.; Cercignani, G.; Murphy, G.; Rossello, A. Synthetic MMP inhibitors: slow-binding behavior of enantioselective N-O-sulfonamido-based inhibitors directed to specific matrixins. Frontiers in CNS and Oncology Medicinal Chemistry, ACS-EFMC, Siena, Italy, October 2007.
54. Tamura, Y.;Watanabe, F.; Nakatani, T.;Yasui, K.; Fuji, M.;Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka, T.; Kawada, K.; Sugita, K.; Ohtani, M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J. Med. Chem. 1998, 41, 640-649.
55. Hodgson, J. Remodeling MMPIs. Matrix metalloproteinase inhibitors will be approved as drugs, probably this year, but questions remain concerning their specificity, bioavailability, and potential long-term toxicity. Biotechnology 1995, 13, 554-557.
56. Chiappori, A. A.; Eckhardt, S. G.; Bukowski, R.; Sullivan, D. M.; Ikeda, M.; Yano, Y.; Yamada-Sawada, T.; Kambayashi, Y.; Tanaka, K.; Javle, M. M.; Mekhail, T.; O'Bryant, C. L.; Creaven, P. J. A phase I pharmacokinetic and pharmacodynamic study of S-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumours. Clin. Cancer Res. 2007, 13, 2091-2099.
57. Bender, S. L.; Melwin, A. A. Metalloproteinase inhibitors, pharmaceutical composition containing them and their pharmaceutical compositions. US 5985900, 1999.
58. Hu, Y.; Xiang, J. S.; DiGrandi, M. J.; Du, X.; Ipek, M.; Laakso, L. M.; Li, J.; Li, W.; Rush, T. S.; Schmid, J.; Skotnicki, J. S.; Tam, S.; Thomason, J. R.;Wang, Q.; Levin, J. I. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg. Med. Chem. 2005, 13, 6629-6644.
59. Xiang, J. S.; Hu, Y.; Rush, T. S.; Thomason, J. R.; Ipek, M.; Sum, P. E.; Abrous, L.; Sabatini, J. J.; Georgiadis, K.; Reifenberg, E.; Majumdar, M.; Morris, E. A.; Tama, S. Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 311-316.
60. Li, J.; Rush, T. S.; Li, W.; DeVincentis, D.; Du, X.; Hu, Y.; Thomason, J. R.; Xiang, J. S.; Skotnicki, J. S.; Tam, S.; Cunningham, K. M.; Chockalingam, P. S.; Morris, E. A.; Levin, J. I. Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 4961-4966.
61. Reiter, L. A.; Robinson, R. P.; McClure, K. F.; Jones, C. S.; Reese, M. R.; Mitchell, P. G.; Otterness, I. G.; Bliven, M. L.; Liras, J.; Cortina, S. R.; Donahue, K. M.; Eskra, J. D.; Griffiths, R. J.; Lame, M. E.; Lopez-Anaya, A.; Martinelli, G. J.; McGahee, S. M.; Yocum, S. A.; Lopresti-Morrow, L. L.; Tobiassen, L. M.; Vaughn-Bowser, M. L. Pyrancontaining sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2004, 14, 3389-3395.
62. Groneberg, R. D.; Burns, C. J.; Morrissette, M. M.; Ullrich, J. W.; Morris, R. L.; Darnbrough, S.; Djuric, S. W.; Condon, S. M.; McGeehan, G. M.; Labaudiniere, R.; Neuenschwander, K.; Scotese, A. C.; Kline, J. A. Dual inhibition of phosphodiesterase 4 andmatrixmetalloproteinases by an (arylsulfonyl)hydroxamic acid template. J.Med. Chem. 1999, 42, 541-544.
63. Bender, S. L.; Broka, C. A.; Campbell, J. A.; Castelhano, A. L.; Fisher, L. E.; Hendricks, R. T.; Sarma, K. Preparation of arylthioalkanoates and analogs as matrix metalloprotease inhibitors. EP 780386, 1997.
64. Burns, C. J.; Groneberg, R. D.; Salvino, J. M.; McGeehan, G.; Condon, S. M.; Morris, R.; Morrissette, M. M.; Matthew, R.; Darnbrough, S.; Neuenschwander, K.; Scotese, A.; Djuric, S. W.; Ullrich, J. W.; Labaudiniere, R. Nanomolar inhibitors for two distinct biological target families from a single synthetic sequence: a next step in combinatorial library design? Angew. Chem. Int. Ed. 1998, 37, 2848-2850.
65. Abbruzzese, T. A.; Guzman, R. J.; Martin, R. L.; Yee, C.; Zarins, C. K.; Dalman, R. L. Matrix metalloproteinase inhibition limits arterial enlargement in a rodent arteriovenous fistula model. Surgery 1998, 124, 328-335.
66. Aranapakam, V.;Davis, J. M.; Grosu, G. T.; Baker, J.; Ellingboe, J.; Zask, A.; Levin, J. I.; Sandanayaka, V. P.; Du, M.; Skotnicki, J. S.; DiJoseph, J. F.; Sung, A.; Sharr, M. A.; Killar, L. M.;Walter, T.; Jin, G.; Cowling, R.; Tillett, J.; Zhao, W.;McDevitt, J.; Xu, Z. B. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4- hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J. Med. Chem. 2003, 46, 2376-2396.
67. Aranapakam, V.; Grosu, G. T.; Davis, J. M.; Hu, B.; Ellingboe, J.; Baker, J.; Skotnicki, J. S.; Zask, A.; DiJoseph, J. F.; Sung, A.; Sharr, M. A.; Killar, L. M.;Walter, T.; Jin, G.; Cowling, R. Synthesis and structure-activity relationship of a-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J. Med. Chem. 2003, 46, 2361-2375.
68. Aranapakam, V.; Davis, J. M.; Grosu, G. T.; Baker, J.; Zask, A.; Levin, J. I.; Ellingboe, J.; Skotnicki, J. S.; DiJoseph, J. F.; Sung, A.; Jin, G.; Xu, W.; McCarthy, D. J.; Barone, D. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumour necrosis factorconverting enzyme and matrix metalloproteinase inhibitors. J. Med. Chem. 2004, 47, 6255-6269.
69. Becker, D. P.;Villamil, C. I.; Barta, T. E.; Bedell, L. J.; Boehm, T. L.; DeCrescenzo, G. A.; Freskos, J. N.; Getman, D. P.; Hockerman, S.; Heintz, R.; Howard, S. C.; Li, M. H.; McDonald, J. J.; Carron, C. P.; Funckes-Shippy, C. L.; Mehta, P. P.; Munie, G. E.; Swearingen, C. A. Synthesis and structure-activity relationships of a- and b-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumour efficacy. J. Med. Chem. 2005, 48, 6713-6730.
70. Noe, M. C.; Snow, S. L.; Wolf-Gouveia, L. A.; Mitchell, P. G.; Lopresti-Morrow, L.; Reeves, L. M.; Yocum, S. A.; Liras, J. L.; Vaughn, M. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase. Bioorg. Med. Chem. Lett. 2004, 14, 4727-4730.
71. Letavic, M. A.; Axt, M. Z.; Barberia, J. A.; Barberia, J. T.; Carty, T. J.; Danley, D. E.; Geoghegan, K. F.; Halim, N. S.; Hoth, L. R.; Kamath, A. V.; Laird, E. R.; Lopresti-Morrow, L. L.; McClure, K. F.; Mitchell, P. G.; Natarajan, V.; Noe, M. C.; Pandit, J.; Reeves, L. M.; Schulte, G. K.; Snow, S. L.; Sweeney, F. J.; Tan, D. H.;Yu, C.H. Synthesis and biological activity of selective pipecolic acid-based TNF-converting enzyme (TACE) inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1387-1390.
72. Bernardo, M. M.; Brown, S.; Li, Z. H.; Fridman, R.; Mobashery, S. Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J. Biol. Chem. 2002, 277, 11201-11207.
73. Ikejiri, M.; Bernardo, M. M.; Meroueh, S. O.; Brown, S.; Chang, M.; Fridman, R.; Mobashery, S. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J. Org. Chem. 2005, 70, 5709-5712.
74. Zhang, Y. M.; Fan, X.; Xiang, B.; Chakravarty, D.; Scannevin, R.; Burke, S.; Karnachi, P.; Rhodes, K.; Jackson, P. Synthesis and SAR of a-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 3096-3100.
75. Rossello, A.; Nuti, E.; Orlandini, E.; Balsamo, A.; Panelli, L. Inhibitors of zinc proteases thioaryl substituted and their use. WO 2008015139, 2008.
76. Pochetti, G.; Gavuzzo, E.; Campestre, C.; Agamennone, M.; Tortorella, P.; Consalvi, V.; Gallina, C.; Hiller, O.; Tschesche, H.; Tucker, P. A.; Mazza, F. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J. Med. Chem. 2006, 49, 923-931.
77. Biasone, A.; Tortorella, P.; Campestre, C.; Agamennone, M.; Preziuso, S.; Chiappini, M.; Nuti, E.; Carelli, P.; Rossello, A.; Mazza, F.; Gallina, C. a-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs. Bioorg. Med. Chem. 2007, 15, 791-799.
78. Folgueras, A. R.; Fueyo, A.; García-Suarez, O.; Cox, J.; Astudillo, A.; Tortorella, P.; Campestre, C.; Gutierrez-Fernandez, A.; Fanjul-Fernandez, M.; Pennington, C. J.; Edwards, D. R.; Overall, C. M.; Lopez-Otín, C. Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J. Biol. Chem. 2008, 283, 9465-9474.
79. Zhang, Y. M.; Fan, X.; Chakaravarty, D.; Xiang, B.; Scannevin, R. H.; Huang, Z.; Ma, J.; Burke, S. L.; Karnachi, P.; Rhodes, K. J.; Jackson, P. F.1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke. Bioorg. Med. Chem. Lett. 2008, 18, 409-413.
80. Puerta, D. T.; Cohen, S. M. Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. Inorg. Chem. 2003, 42, 3423-3430.
81. Puerta, D. T.; Lewis, J. A.; Cohen, S.M. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. J. Am. Chem. Soc. 2004, 126, 8388-8389.
82. Puerta, D. T.; Cohen, S. M.; Lewis, J. A. Metalloprotein inhibitors. US 20070117848, 2007.
83. Zhang, Y. M.; Fan, X.; Yang, S. M.; Scannevin, R. H.; Burke, S. L.; Rhodes, K. J.; Jackson, P. F. Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs). Bioorg. Med. Chem. Lett. 2008, 18, 405-408.
84. Fryer, A.; Frizzi, J. Alkylsulfonamido substituted triazoles as matrix metalloproteinase inhibitors. WO 20080244784 A1, 2008.